ARVINAS, INC. (ARVN) Spending and interest coverage
- R&D / revenue · 12 months: Value 75.40%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 11.59%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 75.40% | Research and development expense / revenue. Period ending 2026-06-30. $238.80M ÷ $316.70M × 100 ≈ 75.40% |
| Stock-based compensation / revenue · 12 months | 11.59% | Share-based compensation / revenue. Period ending 2026-06-30. $36.70M ÷ $316.70M × 100 ≈ 11.59% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 238.80M USD | Research and Development Expense |
| Revenue | 316.70M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 36.70M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -18.10M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $238.80M | $316.70M | $36.70M | $-18.10M | (m) | 75.40% | 11.59% | (m) | (m) |
| 2026-03-31 | $254.70M | $89.40M | $41.10M | $-253.70M | (m) | 284.90% | 45.97% | (m) | (m) |
| 2025-12-31 | $285.20M | $262.60M | $44.00M | $-118.50M | (m) | 108.61% | 16.76% | (m) | (m) |
| 2025-09-30 | $307.40M | $312.30M | $58.80M | $-102.10M | (m) | 98.43% | 18.83% | (m) | (m) |
| 2025-06-30 | $329.60M | $372.80M | $73.30M | $-118.50M | $0.00 | 88.41% | 19.66% | (m) | Reported |
| 2025-03-31 | $354.70M | $426.90M | $84.60M | $-95.50M | $0.00 | 83.09% | 19.82% | (m) | Reported |
| 2024-12-31 | $348.20M | $263.40M | $88.20M | $-250.20M | $0.00 | 132.19% | 33.49% | (m) | Reported |
| 2024-09-30 | $360.10M | $161.10M | $81.60M | $-357.30M | $0.00 | 223.53% | 50.65% | (m) | Reported |
| 2024-06-30 | $359.10M | $93.30M | $73.60M | $-371.00M | $0.00 | 384.89% | 78.89% | (m) | Reported |
| 2024-03-31 | $368.70M | $71.30M | $70.30M | $-397.10M | $0.00 | 517.11% | 98.60% | (m) | Reported |
| 2023-12-31 | $379.70M | $78.50M | $71.60M | $-401.50M | $0.00 | 483.69% | 91.21% | (m) | Reported |
| 2023-09-30 | $382.80M | $159.40M | $75.00M | $-311.80M | (m) | 240.15% | 47.05% | (m) | (m) |
| 2023-06-30 | $374.40M | $158.10M | $77.10M | $-302.10M | (m) | 236.81% | 48.77% | (m) | (m) |
| 2023-03-31 | $346.30M | $137.40M | $78.80M | $-293.20M | (m) | 252.04% | 57.35% | (m) | (m) |
| 2022-12-31 | $315.00M | $131.40M | $75.50M | $-263.20M | (m) | 239.73% | 57.46% | (m) | (m) |
| 2022-09-30 | $278.60M | $112.20M | $72.40M | $-249.80M | (m) | 248.31% | 64.53% | (m) | (m) |
| 2022-06-30 | $241.70M | $91.10M | $68.80M | $-230.00M | (m) | 265.31% | 75.52% | (m) | (m) |
| 2022-03-31 | $209.50M | $65.40M | $63.40M | $-213.60M | (m) | 320.34% | 96.94% | (m) | (m) |
| 2021-12-31 | $180.40M | $46.70M | $57.10M | $-195.30M | $100.00K | 386.30% | 122.27% | -1953.00× | Reported |
| 2021-09-30 | $151.68M | $22.60M | $48.23M | $-184.07M | $48.75K | 671.16% | 213.41% | -3775.76× | Reported |
| 2021-06-30 | $141.09M | $20.90M | $41.25M | $-168.49M | $56.88K | 675.08% | 197.38% | -2962.37× | Reported |
| 2021-03-31 | $121.50M | $21.10M | $34.44M | $-143.09M | $65.00K | 575.81% | 163.22% | -2201.41× | Reported |
| 2020-12-31 | $108.36M | $21.80M | $30.23M | $-124.86M | $65.00K | 497.05% | 138.67% | -1920.88× | Reported |
| 2020-09-30 | $95.57M | $24.40M | $27.10M | $-104.43M | $65.00K | 391.68% | 111.08% | -1606.68× | Reported |
| 2020-06-30 | $82.15M | $22.30M | $23.46M | $-67.18M | $71.65K | 368.37% | 105.19% | -937.59× | Reported |
| 2020-03-31 | $74.73M | $20.50M | $21.01M | $-59.12M | $78.18K | 364.54% | 102.51% | -756.22× | Reported |
| 2019-12-31 | $67.19M | $18.30M | $20.07M | $-51.52M | $85.57K | 367.18% | 109.69% | -602.14× | Reported |
| 2019-09-30 | $61.34M | $16.80M | $20.53M | $-45.68M | $93.95K | 365.13% | 122.22% | -486.17× | Reported |
| 2019-06-30 | $57.90M | $14.79M | $20.99M | $-65.24M | $83.32K | 391.46% | 141.93% | -783.07× | Reported |
| 2019-03-31 | $52.24M | $14.19M | $16.66M | $-55.33M | $70.41K | 368.11% | 117.40% | -785.90× | Reported |
| 2018-12-31 | $45.19M | $14.30M | $11.63M | $-43.80M | $57.44K | 316.04% | 81.33% | -762.57× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $31.39M | $11.75M | (m) | $-24.52M | $44.21K | 267.20% | (m) | -554.58× | Reported |
| 2018-03-31 | $28.88M | $10.02M | (m) | $-22.73M | $47.31K | 288.27% | (m) | -480.32× | Reported |
| 2017-12-31 | $28.79M | $7.58M | $245.05K | $-24.76M | $50.36K | 379.91% | 3.23% | -491.69× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |